Anjarium Biosciences

Developer of next generation non-viral gene therapies

placeSchlieren, Zurich, Switzerland calendar_todayFounded 2016 groups38 employees language anjarium.com

Registered entities

Innovation

1 patent family — focus: Chemistry & metallurgy; filing pace slowing.

YearFilings
20231

Investor mix

5 investors on record; lead investors include Abingworth, Gimv.

Investor typeCountShare
Venture capital240%
Private equity120%
Other / undisclosed240%
Coming soon